Changes in Hong Kong stocks | Baiosetu-B (02315) rose more than 10%, dual-antibody ADC promotes overseas development of pre-clinical CRO and model rats, and the rise in popularity

The Zhitong Finance App learned that Biosetu-B (02315) rose by more than 10%. As of press release, it had risen 10.39% to HK$57.9, with a turnover of HK$80.284,600.

According to the news, Biosetu announced last month that it has signed a global strategic cooperation agreement with Whitehawk Therapeutics, Inc. covering a number of bispecific antibody-conjugated drug (BSAdc) research and development projects. The two sides will jointly promote a diversified next-generation therapeutic product pipeline. According to reports, it only took about four months from the two sides officially starting cooperation to completing the signing of the agreement.

According to Shen Wan Hongyuan, the company's model animal and pre-clinical CRO business has continued to maintain a strong growth trend over the years, and has established deep and close cooperative relationships with the world's leading innovative pharmaceutical companies. High barriers are compounded by industry dividends, and the share is expected to continue to increase. Furthermore, the AI+renMice platform antibody business is being implemented at an accelerated pace, and platform value and R&D transformation are gradually showing.